Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 20,598 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cumulative Irritation Patch Test

NCT01842711
View directory record Official record
Conditions
Allergy, Irritation, Sensitization
Interventions
Not listed
Lead sponsor
Chattem, Inc.
Industry
Eligibility
16 Years to 79 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 19, 2026, 8:54 PM EDT
No Longer Available No phase listed Expanded access

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

NCT02666209
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 2Phase 3 Interventional

Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI

NCT01832363
View directory record Official record
Conditions
Asthma
Interventions
HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control)
Drug · Other
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 19, 2026, 8:54 PM EDT
Terminated Phase 1 Interventional

A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

NCT04986865
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
Interventions
ATG-101
Drug
Lead sponsor
Antengene Biologics Limited
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Oct 19, 2026, 8:54 PM EDT
Terminated Phase 3 Interventional

Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

NCT00004465
View directory record Official record
Conditions
Hemolytic Uremic Syndrome
Interventions
SYNSORB Pk, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Months to 18 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
26
States / cities
Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

NCT00441909
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781, UC-781 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

NCT02459899
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Concord, California • Ventura, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 19, 2026, 8:54 PM EDT
Terminated Phase 2 Interventional Results available

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT00978432
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
RAD001, LBH589, Doublet (RAD001 and LBH589)
Drug
Lead sponsor
Anne Beaven, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 19, 2026, 8:54 PM EDT
Not listed Not applicable Interventional

Evaluation Montelukast in the Treatment of Status Asthmaticus

NCT01770899
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Corrie Fletcher
Other
Eligibility
2 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 2 Interventional

Study of TNFR:Fc (Enbrel) in the Treatment of Asthma

NCT00001893
View directory record Official record
Conditions
Asthma
Interventions
TNFR:Fc
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA

NCT00739921
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Nasal swab under endoscopic guidance
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 19, 2026, 8:54 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

NCT05911321
View directory record Official record
Conditions
Multiple Myeloma, Relapse, Refractory, Aging, Co-morbidity
Interventions
Isatuximab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

NCT05127421
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

NCT00002014
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:54 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

NCT01898286
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
DiaPep277®
Drug
Lead sponsor
Andromeda Biotech Ltd.
Industry
Eligibility
18 Years to 47 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

NCT01969669
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Ketoconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 19, 2026, 8:54 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983
View directory record Official record
Conditions
Bilirubin Encephalopathy
Interventions
usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 27 Weeks
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 19, 2026, 8:54 PM EDT
Withdrawn Phase 2 Interventional

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

NCT04213274
View directory record Official record
Conditions
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
80 mg RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 19, 2026, 8:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile-based Social Services Screening and Referral Tool in an Pediatric Emergency Department

NCT03562910
View directory record Official record
Conditions
Poverty, Social Determinants of Health, Mobile Applications, Pediatric ALL, Emergencies
Interventions
HelpSteps application
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 19, 2026, 8:54 PM EDT
Completed No phase listed Observational

Genetic Study of Families With High Frequency of Hodgkin Lymphoma

NCT02795013
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 19, 2026, 8:54 PM EDT
Active, not recruiting Phase 1 Interventional

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960
View directory record Official record
Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 8:54 PM EDT